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Sleep disturbances occur frequently in patients with Parkinson’s disease (PD).The aim of this study was to investigate the effects of
rotigotine on sleep fluctuations in a sample of PD patients with self-reported complaints of nocturnal awakenings.This prospective,
open-label, observational, and multicenter study enrolled consecutive outpatients with PD and administered rotigotine (mean
dose 8.9mg/day) for 3 months. The primary endpoint was the change from baseline in sleep fragmentation, assessed using the
sleep maintenance subscale score of the Parkinson’s Disease Sleep Scale (PDSS). The newly designed Parkinson’s Disease Sleep
Fragmentation Questionnaire (PD-SFQ) was used to measure other sleep parameters. A total of 62 patients were enrolled (mean
age 70.2 years; 66% male). At 3 months, rotigotine significantly improved sleep fragmentation from baseline on the PDSS-2 sleep
maintenance subscale (from 3.4 ± 0.9 to 1.9 ± 1.4; 𝑃 < 0.0001). Rotigotine also significantly improved nocturnal motor symptoms
(𝑃 < 0.0001), restless legs-like symptoms (𝑃 < 0.005), and nocturia (𝑃 = 0.004). Rotigotine significantly improved self-reported
complaints of sleep fragmentation in PD patients and could be a useful treatment to improve this specific sleep problem in PD.
However, these results are based on a small and clinically heterogeneous sample so they must be taken cautiously.
1. Introduction
Sleep disturbances occur frequently in patients with Parkin-
son’s disease (PD) [1, 2], with up to 70% of patients experi-
encing disrupted sleep in the early to midstages of the disease
[1, 3], increasing up to 90% over time [4]. The diagnosis,
characterization, and management of sleep disorders in
patients with PD are not only based on their frequency but
on the impact they have on quality of life and the prognostic
and clinical correlations that different sleep disorders may
entail [5]. Overall, the presence and severity of sleep disorders
are independent predictors of poorer quality of life [6–8],
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high distress scores [9], severity of nonmotor PD symptoms
[10, 11], and caregiver’s burden [12].
The most frequent sleep disorder in PD is sleep frag-
mentation [13, 14], clinically defined as the presence of
recurrent, involuntary, and frequent nocturnal awakenings
that interrupt normal sleep maintenance. It is one of the
earliest sleep problems to develop, present in 35–50% of
patients within the first 5 years of the disease and increasing
in frequency to 60–70% after 10 years of follow-up [4, 13, 14].
Sleep fragmentation in PD has many etiologies including
nocturnal recurrence of PD symptoms, coexistent sleep
apnea, and nocturia [2, 4]. No specific treatment for sleep
fragmentation is currently established in clinical guidelines,
but some of its causes could be treated by the use of long-
acting dopaminergic agents. Different strategies that provide
a more continuous dopaminergic stimulation, such as the
use of nocturnal apomorphine [15, 16] or levodopa/carbidopa
intestinal gel infusion [17], have been shown to improve sleep
by significant reductions ofmotor PD symptoms at night [18].
Rotigotine, a nonergolinic dopamine receptor agonist,
is formulated as a once-daily transdermal delivery system
to provide stable plasma drug levels over 24 hours. In the
RECOVER study, the rotigotine transdermal patch showed
significant improvements in nocturnal motor impairment
and global sleep quality, but no specific improvements in
sleep maintenance or nocturia were found [19]. As such, the
aim of this study was to assess the efficacy of rotigotine on
sleep fragmentation in a sample of PD patients with self-
reported complaints of unsatisfactory nocturnal awakenings.
To describe in greater detail the different sleep problems
that may influence sleep fragmentation, the Parkinson’s
Disease Sleep Fragmentation Questionnaire (PD-SFQ) was
designed, which has a wider score range (0–24 points) than
the traditional Parkinson’s Disease Sleep Scale (PDSS-2)
and comprises items that measure awakenings per night,
nocturia, restless legs-like symptoms, and nocturnal akinesia.
Furthermore, this study aimed to explore the relationships
of sleep fragmentation—as measured by the PDSS-2 sleep
maintenance subscore—with different nocturnal sleep distur-
bances and the response of different nocturnal disturbances
to rotigotine.
2. Methods
2.1. Study Design and Patients. This prospective, open-label,
observational, and multicenter study enrolled consecutive
outpatients fulfilling research diagnostic criteria of PD [20]
from centers in Spain with hospital-based neurologists expe-
rienced in the treatment of movement disorders. Patients
were recruited over a 6-month period and were followed
up for 3 months. Patients were eligible if they had self-
reported complaints of unsatisfactory nocturnal awakenings
or sleep interruption (determined by subject interview)
in the previous 4 weeks and if a dopamine agonist was
considered the best therapeutic option to improve early-
morning, daytime, or nocturnal PD motor symptoms, as
determined by the investigator. Patients’ disease onset and
medication history (including levodopa daily dose, dopamine
agonist-levodopa equivalent daily dose (DA-LEDD), and
total LEDD) were collected [21]. Patients had to be on stable
doses of drugs in the previous 4 weeks. Patients could be
receiving dopamine agonists other than rotigotine, either as
monotherapy or in combination with levodopa, monoamine
oxidase B inhibitors (selegiline, rasagiline), catechol-O-
methyltransferase inhibitors, or amantadine. When neces-
sary, overnight switch from oral dopamine agonists to trans-
dermal rotigotine patch was performed [22], at equivalent
doses according to previously suggested conversion formulae
[21, 23]. During the study, no changes in the doses of other
PD medications were allowed.
Individuals were excluded if there was suspicion of atyp-
ical or secondary parkinsonism, major psychiatric disorders,
or other conditions known to impair mental status other
than PD, noncompensated systemic diseases (i.e., diabetes,
hypertension, and cancer), or history of skin hypersensitivity
to adhesives or other transdermal therapies.
The study protocol was reviewed and approved by the
Research Ethics Committee of the Hospital de la Santa Creu
i Sant Pau and by the institutional review boards of each
participating center. Written informed consent was obtained
from all participants. A doctor or second party was present to
assess each patient’s capacity to consent.
2.2. Treatment Outcomes and Procedures. The effect of rotig-
otine on sleep fragmentation was assessed using the sleep
maintenance subscale score of the PDSS-2 [24] at baseline
and at 3 months. Motor symptoms were assessed using the
UnifiedParkinson’sDiseaseRating Scale III (UPDRS-III) [25]
and depressive symptoms by the Geriatric Depression Scale
(GDS-15) [26, 27]. Using the PDSS-2, global sleep quality and
various aspects of nocturnal sleep problems in PD were also
assessed and quantified, as described below [28].
A newly designed questionnaire, the PD-SFQ, was also
used to describe different sleep problems that may relate
to sleep fragmentation in more detail. While the PDSS-2
measures sleep maintenance and nocturia by the number of
days a week each symptom appears, the PD-SFQ measures
how many times during the night each sleep disturbance
(awakenings, nocturia, restless legs-like symptoms, and noc-
turnal rigidity) occurs (see Supplementary Material available
online at http://dx.doi.org/10.1155/2015/131508).
Enrolled patients received daily doses of rotigotine for 3
months and were instructed to attend a baseline and follow-
up visit after giving written informed consent. At 1 month,
patients were phoned by the responsible investigator to
discuss if any adverse events had occurred and to assessmotor
function status. A pragmatic dose titration regimen was
conducted by a supervising physician at this time if required.
At baseline and at 3 months, investigators administered the
UPDRS-III, GDS-15, PDSS-2, and PD-SFQ. Total PDSS-2
scores were used to measure global sleep quality and separate
PDSS-2 subscale scores were used to assess some of the
different sleep problems covered by the scale: sleep efficiency
(items 1 and 14), sleep maintenance (item 3), restless legs-like
symptoms (items 4 and 5), nocturnalmotor symptoms (items
9–13), and nocturia (item 8).
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2.3. Statistical Analysis. The PDSS-2 sleep maintenance sub-
scale scoremeasured at baseline and 3monthswas predefined
as the main outcome measure of the study. Secondary
outcome variables included changes in the scores on the PD-
SFQ and PDSS-2 subscales. To measure significant changes
over time, Wilcoxon signed-rank tests were used for items
with narrow score range (0 to 5) and paired-sample 𝑡-tests
were used for scores with a wider range. Mean score changes
from baseline to the final visit were used for bivariate corre-
lations. A repeated-measures general linear model analysis
of variance (GLM ANOVA) was used to build a statistical
model to explore variables affected by various factors and
interactions between factors. Finally, to determine which
sleep symptoms independently predicted improvements in
global sleep quality and sleep fragmentation, multiple step-
wise regression analyses were performed using the PDSS-2
total score and PD-SFQ total score as dependent variables;
those variables that showed a significant relationship in the
univariate analysis were treated as independent variables.
Data are expressed as means ± standard deviation (SD) for
the continuous variables, as percentages for the categorical
variables, and as mean ± SD (range) for the ordinal variables.
Significance was set at 𝑃 < 0.05. All analyses were performed
using SPSS 19.0 (SPSS, Chicago, IL) statistical software.
3. Results
In total, 66 patients were screened and 62 patients with PD
and sleep fragmentation were enrolled (mean age 70.2 years;
66% male; Table 1). The four patients who were screened
and not included in the patient population did not provide
written informed consent and refused enrolment in the
study. At baseline, patients were receiving a mean dose of
rotigotine of 8.5 ± 3.0mg/day. Before starting rotigotine
treatment, 34 patients (54%) were receiving PD treatment
with levodopa and a dopamine agonist, 12 (19.4%) were on
levodopa monotherapy, 8 (12.9%) were on dopamine agonist
monotherapy, and 8 (12.9%) were drug-naı¨ve. All patients
who previously received dopamine agonists were receiving
extended release formulations. Five patients were receiving
entacapone and there was no difference in the number of
patients receiving rasagiline between treatment groups.
At the end of the study, the mean dose of rotigotine was
8.9 ± 3.1mg/day. Two patients dropped out of the study due
to nausea and dizziness.
After 3 months of treatment, rotigotine significantly
improved sleep fragmentation on the PDSS-2 sleep mainte-
nance subscale score (Figure 1). Total PDSS-2 (from 24.3±9.7
to 14.7 ± 8.4; 𝑃 < 0.0001) and UPDRS-III scores (from
23.8 ± 10.7 to 18.4 ± 8.8; 𝑃 < 0.001) were also significantly
improved and GDS-15 scores were modestly improved (from
4.7 ± 3.4 to 4.1 ± 3.4; 𝑃 < 0.043) after 3 months of rotigotine
treatment. No significant interaction between improvement
in the PDSS sleep maintenance subscale scores and 3-month
changes inUPDRS-III (𝑃 = 0.21) or baselineHoehn andYahr
(𝑃 = 0.91) and disease duration (𝑃 = 0.22) was observed.
In the specific sleep disturbances measured by the PDSS-
2, rotigotine also significantly improved nocturnal motor
Table 1: Demographic and clinical features at baseline.
Characteristic Rotigotine (𝑛 = 62)
Age, years 70.2 ± 7 (48–83)
Male, 𝑛 (%) 41 (66.1)
Education, years 9.1 ± 4 (2–20)
Disease duration, years 5.7 ± 4 (0.5–24)
UPDRS-III 23 ± 10 (5–60)
Hoehn and Yahr 2.2 ± 0.8 (1–4)
Total LEDD, mg/day 526 ± 436 (0–1800)
GDS-15 5 ± 4 (0–15)
Total PDSS-2 score 23.5 ± 9 (10–46)
PD-SFQ 10.1 ± 3 (5–20)
Rotigotine dose, mg/day 8.5 ± 3 (4–16)
All values are mean ± standard deviation (range) unless otherwise stated.
GDS-15, Geriatric Depression Scale; LEDD, levodopa equivalent daily dose;
PD-SFQ, Parkinson’s Disease Sleep Fragmentation Questionnaire; PDSS-2,

































Figure 1: Change from baseline in Parkinson’s Disease Sleep
Scale (PDSS) sleep maintenance subscale score after 3 months of
rotigotine treatment.
Table 2: Parkinson’s Disease Sleep Scale (PDSS) subscale scores at
baseline and 3 months in patients with Parkinson’s disease receiving
rotigotine.
PDSS subscale score Baseline 3 months 𝑃 value
Sleep maintenance 3.4 ± 0.9 1.9 ± 1.4 𝑃 < 0.0001
Nocturnal motor symptoms 6 ± 5 3 ± 3 𝑃 < 0.0001
Sleep efficiency 4.3 ± 2 2.3 ± 2 𝑃 < 0.0001
Restless legs-like symptoms 2.5 ± 2 1.4 ± 2 𝑃 < 0.005
Nocturia 3.6 ± 0.9 3.0 ± 1.0 𝑃 < 0.004
symptoms (𝑃 < 0.0001), restless legs-like symptoms (𝑃 <
0.005), and nocturia (𝑃 = 0.004) from baseline (Table 2).
By using mean changes after the initiation of rotigo-
tine, bivariate correlations showed significant improvement
in global sleep quality (measured by PDSS-2 total score)
correlated with mean score decreases in nocturnal motor
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symptoms (𝑟 = 0.80; 𝑃 < 0.001), restless legs-like symptoms
(𝑟 = 0.73; 𝑃 < 0.001), and the PDSS-2 sleep maintenance
subscale score (𝑟 = 0.56; 𝑃 < 0.001). Changes in GDS-15
scores also contributed to better sleep quality, although being
less significant (𝑟 = 0.33; 𝑃 = 0.01).
More specifically, improvement in sleep fragmentation
(measured by the PDSS-2 sleep maintenance subscale) sig-
nificantly correlated with improvement in nocturnal motor
symptoms (𝑟 = 0.34; 𝑃 = 0.008) and restless legs-like
symptoms (𝑟 = 0.27; 𝑃 = 0.02), while changes in GDS-15
(𝑃 = 0.28) and UPDRS-III (𝑃 = 0.26) had no effect on sleep
fragmentation.
In multiple stepwise regression analyses, the change in
PDSS-2 total score with rotigotine at 3 months was indepen-
dently associated with the improvement in nocturnal motor
symptoms (CC=0.53;𝑃 < 0.001), restless legs-like symptoms
(CC = 0.30; 𝑃 < 0.001), and PDSS-2 sleep maintenance
subscale score (CC = 0.30; 𝑃 < 0.001), indicating that
the observed improvement in sleep maintenance score con-
tributed independently to better sleep efficiency. The PDSS-
2 sleep maintenance subscale score was also independently
associated with improvements in restless legs-like symptoms
(CC = 0.37; 𝑃 = 0.02) and to a lesser extent with nocturnal
motor symptoms (CC = 0.22; 𝑃 = 0.04).
When analyzing the effect of rotigotine in patients with
no previous dopamine agonist treatment and in patients
switching from one dopamine agonist to rotigotine, all
differences remained equally significant. In dopamine agonist
na¨ıve patients, minimal interaction between PDSS sleep
maintenance improvement (𝑃 = 0.003) and 3-month change
in UPDRS-III (𝑃 = 0.09) was observed and no interaction
with baseline Hoehn and Yahr (𝑃 = 0.18) or disease
duration (𝑃 = 0.37) occurred. Likewise, GLM ANOVA for
repeated measures found significant improvement of PDSS-
2 maintenance scores for “de novo” PD patients, patients
on levodopa monotherapy, and patients on levodopa-DA
combination therapy (Pillai’s trace;𝑃 < 0.001), with no “Time
× Treatment group” interaction effect (𝑃 = 0.692) and no
significant differences between groups (Tukey’s post hoc tests;
𝑃 > 0.80 for all paired comparisons).
Sleep fragmentation was also significantly improved
when measured using the PD-SFQ. After 3 months of
treatment, rotigotine improved total PD-SFQ scores from
10.1 ± 3.4 to 6.6 ± 2.7 (𝑃 < 0.0001). Interestingly, nocturia
measured by the PD-SFQ (number of nocturia episodes per
night) showed a greater improvement from baseline (from
2.3 ± 1.0 to 1.8 ± 0.8; 𝑃 < 0.0001) than when measured
using the PDSS-2 (days with nocturia per week). In addition,
3-month mean changes in PD-SFQ total scores not only
correlated with mean changes in nocturnal motor symptoms
and restless legs-like symptoms but also correlated with the
PD-SFQ nocturia item (𝑟 = 0.54; 𝑃 < 0.001). The change in
PD-SFQ total score was also independently associated with
improvement in restless legs-like symptoms (CC = 0.37; 𝑃 =
0.02), PD-SFQ nocturia (CC = 0.35; 𝑃 = 0.01), and nocturnal
motor symptoms (CC = 0.22; 𝑃 = 0.04). No interaction
between PD-SFQ total score improvement (𝑃 = 0.001) and 3-
month change in UPDRS-III (𝑃 = 0.60), baseline Hoehn and
Yahr (𝑃 = 0.67), or disease duration (𝑃 = 0.34) was observed.
Rotigotine was well tolerated. No significant adverse
events were reported during the study and no patient stopped
the drug due to worsening ofmotor symptoms or reactions to
the transdermal patch.
4. Discussion
In the present study, treatment with rotigotine was associated
with significant improvements in sleep fragmentation in
a prospective sample of PD patients with subjective and
spontaneous complaints of sleep interruption. The signif-
icant improvement in sleep fragmentation was observed
using both the PDSS-2 and a new questionnaire, the PD-
SFQ, that assesses specific sleep problems that contribute
to the disruption of sleep maintenance in PD. Description
and correlational analysis of those sleep disturbances that
improved with rotigotine showed that better sleep quality
was independently driven by amelioration of nocturnal
motor symptoms, restless legs-like symptoms, and sleep
fragmentation, whereas alleviation of sleep fragmentation
was more specifically driven by improvement in restless legs-
like symptoms.
In the double-bind, placebo-controlled trial RECOVER,
rotigotine improved sleep efficiency by significant ameliora-
tion of the PDSS-2 subscale scores assessing nocturnal and
early-morningmotor symptoms, restless legs-like symptoms,
and pain or muscle cramps [19]. However, in RECOVER
sleep maintenance and nocturia did not improve. This is
a surprising result and may have repercussions in clinical
practice as sleep fragmentation and nocturia are the most
frequent sleep disturbances in PD, and they both contribute
to a poor quality of life [4, 6, 7]. This negative result could
possibly be explained by the recruitment of a heterogeneous
sample of PD patients with and without sleep problems and
by the noncontrolled distribution of patients with or without
sleep fragmentation or nocturia within the two study arms.
To overcome this limitation of the RECOVER study
this study aimed to recruit patients with PD complaining
of sleep interruption. In this sample, we have observed
that restless legs-like symptoms, nocturia, and nocturnal
motor symptoms contributed the most to sleep fragmenta-
tion. The significant improvement observed in these three
clinical domains can be explained by the pharmacokinetic
and pharmacodynamic properties of rotigotine, not only in
striatal dopamine receptors, but also in the spinal cord, and
brainstem nuclei such as medullary raphe nuclei and the
pontine micturition center [29].
The long-acting nature of rotigotine on striatal receptors
seems the most plausible hypothesis for a better control
of Parkinsonian motor symptoms during the night time.
Another long-acting dopamine agonist, cabergoline (added
to levodopa), has been shown to decrease PDSS-2 scores
by improving sleep maintenance and night-time motor
symptoms [30], and other therapies providing continuous
stimulation of basal ganglia circuits, such as deep brain
stimulation [31], nocturnal apomorphine pump [15, 16], and
levodopa/carbidopa intestinal gel infusion [17], have also
shown specific improvement in sleep fragmentation.
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The constant supply of rotigotine over the course of 24
hours and its highest affinity for the D3-receptor [32] may
help to explain its efficacy in restless legs-like symptoms.
Restless legs syndrome reflects a dysfunction of the dorso-
posterior hypothalamic dopaminergic A11 cell group, which
modulates spinal cord excitability mainly through D3 recep-
tors [33, 34]. However, given the similar D3 receptor affinity
among pramipexole, ropinirole, and rotigotine, we suggest
that the higher benefit shown by rotigotine on restless legs-
like symptoms may be mostly based on a more continuous
dopaminergic stimulation during the night. Additionally, the
observed improvements in nocturia could be explained by
a better dopaminergic and serotoninergic control exerted
by rotigotine on brainstem nuclei. The pontine micturition
center is rich in dopamine receptors that inhibit its excitabil-
ity through projections from the ventral tegmental area
[35], and the functionality of the medullary raphe nuclei—
that control bladder overactivity and detrusor contractility—
could be improved by the specific affinity of rotigotine on 5-
hydroxytryptamine 1A receptors [36, 37].
Overall, the selection of patients with self-reported
complaints of sleep fragmentation recruited prospectively
from daily clinical practice allowed for the observation that
rotigotine may improve this specific sleep problem, a finding
that was not shown in the RECOVER study. Significant
improvement of nocturia after onset of rotigotine and its
independent contribution for improving sleep fragmentation
were more clearly reflected by assessing this phenomenon
with the PD-SFQ, which indicates the number of nocturia
episodes per night instead of the number of days per week
with nocturia assessed in the PDSS-2.Thenumber of nocturia
episodes per night therefore appears to be a clinically and
scientifically relevant variable that should be taken into
account in future interventional studies. However, it must be
noted that the PD-SFQ has not yet been properly validated,
and future studies should assess its validity and accuracy.
Some other limitations of our study must be acknowl-
edged. This is an open-label trial, the primary outcome was
based on subjective reports, the sample size was not large
enough so as to establish firm conclusions, and patients were
followed up for only three months. In addition, other sleep
problems that can only be assessed using polysomnography,
such as sleep disordered breathing, REM sleep behavior
disorder, and periodic limb movement syndrome, were not
analyzed. However, based on these preliminary results com-
ing from daily clinical practice further research is warranted.
A larger sample of patients and a more detailed examination
of sleep-related problems contributing to sleep fragmentation
using polysomnography or actigraphy would help to verify
the potential benefits of rotigotine on different sleep parame-
ters. Finally, given the open-label design of the study,we could
not evaluate properly whether the effect of rotigotine on sleep
fragmentation was ascribed exclusively to a placebo effect.
5. Conclusions
Rotigotine significantly improved self-reported complaints of
sleep fragmentation in PD patients and could be a useful
treatment to improve this specific sleep problem in PD. The
sample in this open-label study is small and clinically het-
erogeneous, including “de novo” and advanced patients and
patients in previous treatment with and without dopamine
agonists and, in accordance, the observed results must be
taken cautiously.
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